遗传 ›› 2021, Vol. 43 ›› Issue (1): 30-39.doi: 10.16288/j.yczz.20-315

• 综述 • 上一篇    下一篇

肺部微生物组通过炎症反应介导慢性阻塞性肺疾病转化为肺癌的研究进展

王娅洁, 吴爽爽, 储江(), 孔祥阳()   

  1. 昆明理工大学医学院疾病与药物遗传实验室,昆明 650500
  • 收稿日期:2020-11-24 修回日期:2020-12-28 出版日期:2021-01-20 发布日期:2021-01-12
  • 通讯作者: 储江,孔祥阳 E-mail:chujiang2015@126.com;kxy2772@yahoo.com
  • 作者简介:王娅洁,在读硕士研究生,专业方向:遗传学。E-mail: 1186958954@qq.com
  • 基金资助:
    昆明理工大学省级人培项目编号(KKSY201660006)

Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation

Wang Yajie, Wu Shuangshuang, Chu Jiang(), Kong Xiangyang()   

  1. Genetics and Pharmacogenomics Laboratory, Medical School, Kunming University of Science and Technology, Kunming 650500, China
  • Received:2020-11-24 Revised:2020-12-28 Online:2021-01-20 Published:2021-01-12
  • Contact: Chu Jiang,Kong Xiangyang E-mail:chujiang2015@126.com;kxy2772@yahoo.com
  • Supported by:
    Supported by Provincial Training Program of Kunming University of Science and Technology No(KKSY201660006)

摘要:

肺部微生物组存在于呼吸道和实质组织中,通过菌群紊乱、代谢产物、炎症反应、免疫反应、基因毒性等方面介导肺部损伤。随着肺部微生物组的深入研究,发现肺部微生物组的相关活动与慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)和肺癌息息相关,能够促使COPD向肺癌的转变。本文主要介绍了肺部微生物组稳态及其通过炎症反应导致COPD和肺癌,重点探讨了肺部微生物组如何通过炎症反应介导COPD转化为肺癌,以期为COPD和肺癌的临床预防、优化治疗以及新型药物设计提供新的理论依据。

关键词: 肺部微生物组, 慢性阻塞性肺疾病(COPD), 肺癌, 多样性, 炎症

Abstract:

Lung microbiome exists in the respiratory tract and parenchymal tissues. It mediates lung injury through a variety of mechanisms, including bacterial disturbance, metabolites, inflammatory response, immune response, and genotoxicity. Accumulating evidences suggest that changes in lung microbiome correlates with chronic obstructive pulmonary disease (COPD) and lung cancer, and the microbiome promotes the progression from COPD to lung cancer. In this review, we mainly introduce the impairment of the homeostasis of the lung microbiome and its inflammation that leads to COPD and lung cancer, then focus on how the microbiome mediates the progression from COPD to lung cancer through inflammatory response. The review may provide a new theoretical basis for clinical prevention, optimal treatment strategy and design of new drugs for COPD and lung cancer.

Key words: lung microbiome, chronic obstructive pulmonary disease, lung cancer, diversity, inflammation